Trial Profile
A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Rituximab (Primary) ; Vinorelbine (Primary) ; Pegfilgrastim
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Mar 2012 Additional lead trial investigators (Stefanovic A) identified as reported by ClinicalTrials.gov.
- 27 Apr 2009 New trial record